Literature DB >> 16884817

Effects of type of smoking (pipe, cigars or cigarettes) on biological indices of tobacco exposure and toxicity.

Christian Funck-Brentano1, Mathilde Raphaël, Michel Lafontaine, Jean-Pierre Arnould, Céline Verstuyft, Martine Lebot, Dominique Costagliola, Ronan Roussel.   

Abstract

Although all forms of smoking are harmful, smoking pipes or cigars is associated with lower exposure to the lethal products of tobacco products and lower levels of morbidity and mortality than smoking cigarettes. Cytochrome P-450-1A (CYP1A) is a major pathway activating carcinogens from tobacco smoke. Our primary aim was to compare CYP1A2 activity in individuals smoking pipes or cigars only, cigarettes only and in non-smokers. We studied 30 smokers of pipes or cigars only, 28 smokers of cigarettes only, and 30 non-smokers male subjects matched for age. CYP1A2 activity was assessed as the caffeine metabolic ratio in plasma. One-day urine collection was used for determining exposure to products of tobacco metabolism. Nitrosamine and benzo[a]pyrene DNA adducts were measured in lymphocytes. CYP1A2 activity was greater (p<0.0001) in cigarette smokers (median: 0.61; interquartile range: 0.52-0.76) than in pipe or cigar smokers (0.27; 0.21-0.37) and non-smokers (0.34; 0.25-0.42) who did not differ significantly. Urinary cotinine and 1-hydroxypyrene levels were higher in cigarette smokers than in pipe or cigar smokers and higher in the later than in non-smokers. DNA adducts levels were significantly lower in pipe or cigar smokers than in cigarette smokers. In multivariate analysis, cigarette smoking was the only independent predictor of CYP1A2 activity (p<0.0001) and of 1-hydroxypyrene excretion in urine (p=0.0012). In this study, pipe or cigar smoking was associated with lower exposure to products of tobacco metabolism than cigarette smoking and to an absence of CYP1A2 induction. Cigarette smoking was the only independent predictor of CYP1A2 activity in smokers. However, inhalation behaviour, rather than the type of tobacco smoked, may be the key factor linked to the extent of tobacco exposure and CYP1A2 induction. Our results provide a reasonable explanation for the results of epidemiological studies showing pipe or cigar smoking to present fewer health hazards than cigarette smoking.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16884817     DOI: 10.1016/j.lungcan.2006.06.016

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  10 in total

1.  Applications of CYP-450 expression for biomonitoring in environmental health.

Authors:  Ho-Sun Lee; Mihi Yang
Journal:  Environ Health Prev Med       Date:  2008-02-28       Impact factor: 3.674

Review 2.  Biomarkers of exposure to new and emerging tobacco delivery products.

Authors:  Suzaynn F Schick; Benjamin C Blount; Peyton Jacob; Najat A Saliba; John T Bernert; Ahmad El Hellani; Peter Jatlow; R Steven Pappas; Lanqing Wang; Jonathan Foulds; Arunava Ghosh; Stephen S Hecht; John C Gomez; Jessica R Martin; Clementina Mesaros; Sanjay Srivastava; Gideon St Helen; Robert Tarran; Pawel K Lorkiewicz; Ian A Blair; Heather L Kimmel; Claire M Doerschuk; Neal L Benowitz; Aruni Bhatnagar
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-05-18       Impact factor: 5.464

3.  Smoky coal, tobacco smoking, and lung cancer risk in Xuanwei, China.

Authors:  Christopher Kim; Robert S Chapman; Wei Hu; Xingzhou He; H Dean Hosgood; Larry Z Liu; Hong Lai; Wei Chen; Debra T Silverman; Roel Vermeulen; Linwei Tian; Bryan Bassig; Min Shen; Yawei Zhang; Shuangge Ma; Nathaniel Rothman; Qing Lan
Journal:  Lung Cancer       Date:  2014-01-11       Impact factor: 5.705

4.  Biomarkers of Exposure among U.S. Adult Cigar Smokers: Population Assessment of Tobacco and Health (PATH) Study Wave 1 (2013-2014).

Authors:  Cindy M Chang; Brian L Rostron; Joanne T Chang; Catherine G Corey; Heather L Kimmel; Connie S Sosnoff; Maciej L Goniewicz; Kathryn C Edwards; Dorothy K Hatsukami; Yuesong Wang; Arseima Y Del Valle-Pinero; Maocheng Yang; Mark J Travers; Stephen Arnstein; Kristie Taylor; Kevin Conway; Bridget K Ambrose; Nicolette Borek; Andrew Hyland; Lanqing Wang; Benjamin C Blount; Dana M van Bemmel
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2019-02-07       Impact factor: 4.254

Review 5.  Non-cigarette tobacco products: what have we learnt and where are we headed?

Authors:  Richard J O'Connor
Journal:  Tob Control       Date:  2012-03       Impact factor: 7.552

Review 6.  Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease.

Authors:  Klaus F Rabe
Journal:  Br J Pharmacol       Date:  2011-05       Impact factor: 8.739

7.  The association of pipe and cigar use with cotinine levels, lung function, and airflow obstruction: a cross-sectional study.

Authors:  Josanna Rodriguez; Rui Jiang; W Craig Johnson; Barbara A MacKenzie; Lewis J Smith; R Graham Barr
Journal:  Ann Intern Med       Date:  2010-02-16       Impact factor: 25.391

8.  Population pharmacokinetic modelling of roflumilast and roflumilast N-oxide by total phosphodiesterase-4 inhibitory activity and development of a population pharmacodynamic-adverse event model.

Authors:  Gezim Lahu; Andreas Hünnemeyer; Edgar Diletti; Martin Elmlinger; Peter Ruth; Karl Zech; Nigel McCracken; Axel Facius
Journal:  Clin Pharmacokinet       Date:  2010-09       Impact factor: 6.447

9.  Pharmacokinetic and Pharmacodynamic Modelling to Characterize the Tolerability of Alternative Up-Titration Regimens of Roflumilast in Patients with Chronic Obstructive Pulmonary Disease.

Authors:  Axel Facius; Eleonora Marostica; Philip Gardiner; Henrik Watz; Gezim Lahu
Journal:  Clin Pharmacokinet       Date:  2018-08       Impact factor: 6.447

10.  Hookah smoking and cancer: carcinoembryonic antigen (CEA) levels in exclusive/ever hookah smokers.

Authors:  Khan Mohammad Sajid; Kamal Chaouachi; Rubaida Mahmood
Journal:  Harm Reduct J       Date:  2008-05-24
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.